Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)

Two Sigma Investments LP purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 21,628 shares of the company’s stock, valued at approximately $78,000.

A number of other institutional investors also recently modified their holdings of ATYR. Group One Trading LLC bought a new stake in Atyr PHARMA during the fourth quarter worth about $26,000. Victory Capital Management Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth about $37,000. Raymond James Financial Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth about $39,000. XTX Topco Ltd acquired a new position in Atyr PHARMA during the fourth quarter worth approximately $40,000. Finally, Boothbay Fund Management LLC acquired a new position in Atyr PHARMA during the fourth quarter worth approximately $53,000. 61.72% of the stock is currently owned by institutional investors.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR opened at $5.20 on Friday. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $5.98. The stock has a market cap of $462.82 million, a price-to-earnings ratio of -5.53 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm’s 50-day simple moving average is $3.75 and its 200 day simple moving average is $3.60.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, research analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Leerink Partners began coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Wednesday, June 4th. Finally, Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.